Illustration: Radina Dobrinova for Endpoints News
August 17, 2023 07:00 AM EDTUpdated 10:36 AM
R&D
In Focus
Diagnostics

His tiny pre­na­tal test­ing com­pa­ny has big plans af­ter ex­act­ing le­gal re­venge on lab gi­ants

Jared Whitlock

Features Editor

Ravin­der Dhal­lan’s name is on key patents in non­in­va­sive pre­na­tal test­ing, a field that has re­shaped screen­ing for ex­pec­tant moth­ers. But he was a mi­nor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times